Article

Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy.

Department of Medicine (Hematology, Oncology, and Transplant) and.
STEM CELLS TRANSLATIONAL MEDICINE (Impact Factor: 3.6). 03/2013; DOI: 10.5966/sctm.2012-0084
Source: PubMed

ABSTRACT Adoptive transfer of antitumor lymphocytes has gained intense interest in the field of cancer therapeutics over the past two decades. Human natural killer (NK) cells are a promising source of lymphocytes for anticancer immunotherapy. NK cells are part of the innate immune system and exhibit potent antitumor activity without need for human leukocyte antigen matching and without prior antigen exposure. Moreover, the derivation of NK cells from pluripotent stem cells could provide an unlimited source of lymphocytes for off-the-shelf therapy. To date, most studies on hematopoietic cell development from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) have used incompletely defined conditions and been on a limited scale. Here, we have used a two-stage culture system to efficiently produce NK cells from hESCs and iPSCs in the absence of cell sorting and without need for xenogeneic stromal cells. This novel combination of embryoid body formation using defined conditions and membrane-bound interleukin 21-expressing artificial antigen-presenting cells allows production of mature and functional NK cells from several different hESC and iPSC lines. Although different hESC and iPSC lines had varying efficiencies in hematopoietic development, all cell lines tested could produce functional NK cells. These methods can be used to generate enough cytotoxic NK cells to treat a single patient from fewer than 250,000 input hESCs/iPSCs. Additionally, this strategy provides a genetically amenable platform to study normal NK cell development and education in vitro.

Download full-text

Full-text

Available from: Laurence Cooper, Jun 28, 2015
0 Followers
 · 
205 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: The use of cells derived from hiPSCs as cellular therapy for myocardial injury has yet to be examined in a large-animal model. METHODS AND RESULTS: Immuno-suppressed Yorkshire pigs were assigned to one of three groups; MI: distal LAD ligation and reperfusion (n=13), CELL: MI with 4x10(6) hiPSC-VCs administered via a fibrin patch (n=14), Normal (n=15). At 4 weeks, LV structural and functional abnormalities were less pronounced in CELL hearts than in MI hearts (p<0.05), and these improvements were accompanied by declines in scar size (10.4±1.6% vs. 8.3±1.1%; MI vs CELL, p<0.05). CELL was associated with significant increase of vascular density and blood flow (0.83±0.11 and 1.05±0.13 ml/min per g, MI vs. CELL, p<0.05) in the peri-scar border zone (BZ), which was accompanied by improvements in systolic thickening fractions (IZ: -10±7% vs. 5±5%; BZ: 7±4% vs. 23±6%; p<0.05). hiPSC-VC transplantation stimulated c-kit+ cell recruitment to BZ and the rate of bromodeoxyuridine incorporation in both c-kit+ cells and cardiomyocytes (p<0.05). Using a magnetic resonance spectroscopic saturation transfer technique, we found that the rate of ATP hydrolysis in BZ of MI hearts was severely reduced, the severity of this reduction was linearly related to the severity of the elevations of wall stresses (r=0.82, p<0.05). This decline in BZ ATP utilization was markedly attenuated in the CELL group. CONCLUSIONS: hiPSC-VC transplantation mobilized endogenous progenitor cells into the BZ, attenuated regional wall stress, stimulated neovascularization, and improved BZ perfusion, which in turn resulted in marked increases of BZ contractile function and ATP turnover rate.
    Circulation 01/2013; 127(9). DOI:10.1161/CIRCULATIONAHA.112.000641 · 14.95 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human embryonic stem cell (hESC) derived NK cells are a promising source of anti-tumor lymphocytes for off-the-shelf immunotherapeutics. They also provide a genetically tractable platform uniquely suited for study of anti-tumor immunotherapies in pre-clinical models. We have previously demonstrated the potency of hESC-derived NK cells in vivo. We have used both bioluminescent and fluorescent imaging to demonstrate trafficking of hESC-derived NK cells to tumors in vivo. Our dual-imaging approached allowed us to more specifically define and study the kinetics of NK cell trafficking to tumor sites. NK cell persistence and trafficking were further evaluated by flow cytometry and immunohistochecmistry. This integrated approach provides an improved system to study the kinetics and biodistribution of adoptively transferred lymphocytes which is broadly applicable to the field of immunotherapy.
    Stem cells and development 02/2013; DOI:10.1089/scd.2012.0608 · 4.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Colorectal tumours are actually considered as aberrant organs, within it is possible to notice a different stage of cell growth and differentiation. Their origin is reported to arise from a subpopulation of tumour cells endowed with, just like the healthy stem cells, self-renewal and aberrant multi-lineage differentiation capacity likely to be called colorectal cancer stem cells (CCSCs). Cancer stem cells (CSCs) fate, since their origin, reflects the influences from their microenvironment (or niche) both in the maintenance of stemness, in promoting their differentiation, and in inducing epithelial-mesenchymal transition, responsible of CSCs dissemination and subsequent formation of metastatic lesions. The tumour cells heterogeneity and their immuno-response resistance nowadays probably responsible of the failure of the conventional therapies, make this research field an open issue. Even more importantly, our increasing understanding of the cellular and molecular mechanisms that regulate CSC quiescence and cell cycle regulation, self-renewal, chemotaxis and resistance to cytotoxic agents, is expected to eventually result in tailor-made therapies with a significant impact on the morbidity and overall survival of colorectal cancer patients.
    Molecular Aspects of Medicine 08/2013; 39. DOI:10.1016/j.mam.2013.07.001 · 10.30 Impact Factor